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Abstract
Background: The wide availability of the Internet and the growth of digital communication technologies have become an
important tool for epidemiological studies and health surveillance. Influenzanet is a participatory surveillance system monitoring
the incidence of influenza-like illness (ILI) in Europe since 2003. It is based on data provided by volunteers who self-report their
symptoms via the Internet throughout the influenza season and currently involves 10 countries.
Objective: In this paper, we describe the Influenzanet system and provide an overview of results from several analyses that
have been performed with the collected data, which include participant representativeness analyses, data validation (comparing
ILI incidence rates between Influenzanet and sentinel medical practice networks), identification of ILI risk factors, and influenza
vaccine effectiveness (VE) studies previously published. Additionally, we present new VE analyses for the Netherlands, stratified
by age and chronic illness and offer suggestions for further work and considerations on the continuity and sustainability of the
participatory system.
Methods: Influenzanet comprises country-specific websites where residents can register to become volunteers to support
influenza surveillance and have access to influenza-related information. Participants are recruited through different communication
channels. Following registration, volunteers submit an intake questionnaire with their postal code and sociodemographic and
medical characteristics, after which they are invited to report their symptoms via a weekly electronic newsletter reminder. Several
thousands of participants have been engaged yearly in Influenzanet, with over 36,000 volunteers in the 2015-16 season alone.
Results: In summary, for some traits and in some countries (eg, influenza vaccination rates in the Netherlands), Influenzanet
participants were representative of the general population. However, for other traits, they were not (eg, participants underrepresent
the youngest and oldest age groups in 7 countries). The incidence of ILI in Influenzanet was found to be closely correlated although
quantitatively higher than that obtained by the sentinel medical practice networks. Various risk factors for acquiring an ILI
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infection were identified. The VE studies performed with Influenzanet data suggest that this surveillance system could develop
into a complementary tool to measure the effectiveness of the influenza vaccine, eventually in real time.
Conclusions: Results from these analyses illustrate that Influenzanet has developed into a fast and flexible monitoring system
that can complement the traditional influenza surveillance performed by sentinel medical practices. The uniformity of Influenzanet
allows for direct comparison of ILI rates between countries. It also has the important advantage of yielding individual data, which
can be used to identify risk factors. The way in which the Influenzanet system is constructed allows the collection of data that
could be extended beyond those of ILI cases to monitor pandemic influenza and other common or emerging diseases.
(JMIR Public Health Surveill 2017;3(3):e66)   doi:10.2196/publichealth.7429
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Introduction
Influenza is a global public health problem—whether seasonal,
zoonotic, or pandemic—causing high general practice
consultation rates, increased hospital admissions, excess deaths,
and high absenteeism in schools and workplaces, including in
health workers. Its high socioeconomic impact and burden is
not just limited to the industrialized world but extends to low-
and middle-income countries, encompassing multiple
dimensions such as direct costs to the health service and
households and indirect costs because of productivity losses,
as well as broadly affecting the overall economy [1].
Influenzanet [2] is a participatory monitoring system for
influenza-like illness (ILI) based on data reported by Internet
users among the general population who volunteer as
participants. It was initially conceived to make scientific
information accessible to a broad public and to promote
students’ enthusiasm for science [3,4]. It was first launched in
the Netherlands and Belgium as “The Great Influenza Survey”
(De Grote Griepmeting [5]) in the 2003-04 influenza season.
In 2005, Portugal joined (Gripenet [6]). Subsequently, the
system was adopted by Italy (Influweb [7]) in 2008, the United
Kingdom (Flusurvey [8]) in 2009, Sweden (Hälsorapport [9])
in 2011, France (Grippenet [10]) and Spain (Gripenet.es [11])
in 2012, and Ireland (Flusurvey.ie [12]) and Denmark
(Influmeter [13]) in 2013. Switzerland joined in December 2016;
however, at the moment of the writing of the paper, there were
not enough data to be included in the analysis.
In 2009, the Influenzanet consortium was established to foster
collaboration and pool resources toward using this uniform
system of participatory ILI surveillance across Europe.
Hereafter, we will refer to the system in each country as
Influenzanet, instead of designating it by the actual name by
which the system is known in each country. The Portuguese
team also helped to introduce the system in Latin America,
namely in Mexico (Reporta [14]) and supported the development
of a similar system in Brazil but focused on dengue instead
(Dengue na Web [15]). Similar systems were independently
implemented in Australia (Flu Tracking [16]), the United States
(Flu Near You [17]), and Germany (GrippeWeb [18]).
Additionally, Salud Boricua [19] was launched in Puerto Rico,
targeting 3 different acute febrile illnesses, which included
influenza, dengue, and leptospirosis. Figure 1 (updated from
[20]) shows a timeline of the launch date of the participatory
surveillance systems for ILI in Europe and worldwide.
Figure 1. Timeline of Influenzanet (in blue) and other participatory surveillance systems for influenza-like illness.
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Here, we describe the Influenzanet participatory surveillance
system and provide an overview of the results obtained from
different analyses performed with the data, including
representativeness analyses, data validation (comparing ILI
incidence rates between Influenzanet and sentinel medical
practice networks), identification of ILI risk factors, and
influenza vaccine effectiveness (VE) studies previously
published. Additionally, we present new VE analyses for the
Netherlands, stratified by age and chronic illness, and offer
suggestions for further work and considerations on the continuity
and sustainability of the participatory system.
Methods
Influenzanet Data Collection
Any resident of a participating country can register on its
national website by completing a simple Web-based intake
questionnaire containing various sociodemographic, medical,
and behavioral questions, in addition to the questions about
postal code of residence and workplace (see Multimedia
Appendix 1). Once registered, participants receive a weekly
email newsletter with a reminder to complete a short symptoms
questionnaire. In this questionnaire, participants are asked to
report any symptoms that they have experienced since their
previous visit to the Influenzanet website. If symptoms are
reported, participants are asked to provide further information,
including the date of onset, whether these led to a change of
behavior (eg, missing school or work or taking medicines), and
whether the participant visited a medical service, and if so, the
outcome of the consultation. The system allows participants to
also report for other members of their household to foster data
collection for children and elderly people. On the basis of a
unique user identifier, participants can be followed over multiple
seasons and are urged to update changes in sociodemographic,
medical, behavioral, residential, and workplace information
every season.
Participation Rates
Several thousands of participants have been engaged yearly in
Influenzanet, with over 36,000 volunteers in the last season of
2015-16. On the basis of the 2015-16 season, the Netherlands
had the highest number of participants who completed at least
3 symptoms questionnaires (13,821 participants corresponding
to 0.08% of the country’s population), followed by France
(6413; 0.01%), the United Kingdom (5134; 0.01%), Belgium
(Dutch-speaking region: 4559; 0.07%), Sweden (3245; 0.03%),
Portugal (1840; 0.02%), Italy (1822; 0.003%), Denmark (1541;
0.03%), Ireland (575; 0.01%), and Spain (487; 0.001%). Data
for Sweden are for the 2013-14 season, as after that Sweden
started using Influenzanet through invitation only to improve
the representativeness of the monitored sample and compare it
with the previous seasons. Figure 2 compares the participation
rates across countries versus the country’s population [21].
Figure 2. Participation rates across the 10 Influenzanet countries. Percentage of Influenzanet active participants (B) among each country’s total population
(C). Source: Influenzanet 2015-16 data for all countries, except for Sweden where data are for 2013-14; Country population per January 1, 2016 (Sweden
per January 1, 2014)—the Netherlands (NL): 17 million (M), Belgium (BE): 7M, Portugal (PT): 10M; Italy (IT): 60M; The United Kingdom (UK):
65M; Sweden (SE): 10M; France (FR): 65M; Spain (ES): 46M; Ireland (IE): 5M; and Denmark (DK): 6M.
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The number of participants has been relatively stable over the
years for the countries that first started (after having increased
during their first seasons) and is still increasing for the countries
that joined after 2011. For example, of all participants who
completed at least 3 symptoms questionnaires during a season
(hereafter referred as active participants) analyzed from 2003-04
to 2012-13, on average in the Netherlands, 76% (Standard
deviation [SD] 8; N=16,481) participated again in the following
season, with 69% (SD 12; N=1894) in Portugal, whereas
Belgium and Italy had values within that range [22]. During the
influenza season from November 2013 until May 2014 (29
weeks of survey), 73% (9479/12,985) of the participants in the
Netherlands completed the survey more than 20 times; 68%
(7964/11,758) of the completed surveys were less than 9 days
apart, reflecting a high level of engagement of the participants
with the system [4].
Ethical Approval
In all the participating countries, Influenzanet studies were
conducted in agreement with national regulations on privacy
and data collection and treatment. Informed consent was
obtained from individuals who participated in the studies
enabling the collection, storage, treatment, and publication of
data in anonymized, processed, and aggregated forms for
scientific purposes. The Grote Griepmeting study is carried out
according to the Dutch legislation on privacy, and the privacy
regulation of the studies was approved by the Dutch Data
Protection Authority. In Portugal, the Gripenet project was
approved by the Ethics Committee of the Instituto Gulbenkian
de Ciência, and the Portuguese Data Protection Commission
approved the Gripenet study (Authorization Number 2868). In
the United Kingdom, the Flusurvey was approved by the London
School of Hygiene and Tropical Medicine Ethics Committee
(Application Number 5530). In Sweden, the Influensaskoll study
was approved by the Stockholm Regional Ethical Review Board
(Dnr. 2011/387-31/4). In France, the Grippenet study was
approved by the French Advisory Committee for research on
information treatment in the field of health (ie, CCTIRS,
authorization 11.565) and by the French National Commission
on Informatics and Liberty (authorization DR-2012-024).
Results
Participant Representativeness
In Web-based surveys, the nonrepresentative nature of the
Internet-using population can result in a selection bias [3]. In
addition, people who do not experience any ILI symptoms may
not consider themselves suitable for participation. Accordingly,
representativeness analyses have been performed at various
stages during the activity of Influenzanet to compare the
demographic and health characteristics of the participants with
those in the country's overall population.
In work from 2006, it was shown that the demographic and
health characteristics of the participants in the Netherlands were
remarkably similar with those observed by the National
Information Network of General Practicioners (at that time
Landelijk Informatie Netwerk Huisartsenzorg abbreviated as
LINH; [3]). Namely, striking similarities were found between
Dutch Influenzanet participants (N=13,000) and the population
observed by the general practitioners (GPs) in LINH
(N=255,000) with regard to the prevalence of asthma (6.9% in
Influenzanet, n=918 vs 6.4% in LINH, n=6320) and influenza
vaccination rates and, to a lesser degree, for diabetes (2.4% in
Influenzanet, n=319 vs 3.5% in LINH, n=8925; P<.005). The
vaccination rates in patients with asthma, diabetes, and persons
older than 65 years were 68% (n=9044), 85% (n=11,305), and
85% (n=11,305), respectively, among Dutch Influenzanet
participants, whereas the corresponding percentages in the LINH
population were 73% (191,250), 85% (216,750), and 87%
(221,850). Similar results were obtained for Belgium [23] and
the United Kingdom [24] in terms of risk group status.
In 2011-12, Influenzanet launched a standardized common
framework for data collection. A study of representativeness
was then extended to all participating countries (7 at that time)
to assess the representativeness of the sample in terms of a set
of demographic, geographic, socioeconomic, and health
indicators [25]. The Influenzanet population was not
representative of the general population in terms of age
distribution, underrepresenting the youngest and the oldest age
groups. However, all age classes were represented. The gender
imbalance differed between countries, although higher female
participation occurred in most countries (the Netherlands, the
United Kingdom, Sweden, and France). Differences between
gender-specific information-seeking behavior (more prominent
in women) and Internet usage (with higher rates in male
populations) may have been at the origin of these gender
imbalances. For instance, the countries with higher Internet
usage by males were also the countries either having a larger
prevalence of male Influenzanet participants (Belgium and Italy)
or displaying similar participation of males and females
(Portugal).
In the aforementioned 2011-12 representativeness study [25],
smokers were underrepresented in the majority of countries, as
were individuals with diabetes; the representativeness of asthma
prevalence and influenza vaccination coverage for ≥65 years
individuals in 2 successive seasons (2010-11 and 2011-12)
varied between countries. Additionally, participants from most
countries were found to be more frequently employed than the
general population, except in the Netherlands where the contrary
was observed, and in the United Kingdom where no significant
difference was found. Participants also tended to have a higher
education level than the general population, as shown by results
from the 3 countries where such data were available to compare
with Influenzanet data (France, Portugal, and Sweden; [25,26]).
Quantifying these biases allows them to be taken into account
in future analyses of Influenzanet epidemiological studies.
Influenzanet Versus Traditional ILI Surveillance
Influenza surveillance in Europe is traditionally pooled by the
European Influenza Surveillance Network (EISN), which
combines epidemiological and virological surveillance of
influenza. The EISN network includes a set of sentinel GPs in
each country who collect information from patients reporting
symptoms of ILI. The sentinel GPs report the aggregated number
of ILI consultations, by age group, to the EISN via The
European Surveillance System (TESSy) database, based on
which the EISN calculates the ILI rates. A sample of these
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patients is also tested for virological confirmation of influenza.
The sentinel GPs usually represent 1% to 5% of the GPs working
in the country or region [27].
The EISN is coordinated by the European Centre for Disease
Control and Prevention (ECDC) since 2008 and participates in
the wider World Health Organization (WHO) Regional Office
for European Region influenza network and in the WHO Global
Influenza Surveillance and Response System. Since 2014, the
ECDC and WHO/Europe have a single joint Web-based bulletin
called “Flu News Europe” [28].
The incidence of ILI among Influenzanet participants is
determined in near real time using a syndromic case definition.
From season 2011-12 onwards, all Influenzanet countries apply
the case definition for ILI recommended by the ECDC when
reporting feedback to participants on whether their reported
symptoms might be due to ILI. Additionally, as the participants’
individual symptoms data are available, this enables exploring
different case definitions when analyzing the data (see Textbox
1). Graphic representation of the results is dynamically updated
on the Influenzanet website.
Previous studies have established a positive correlation between
the incidence of ILI determined by Influenzanet and that
estimated through the clinical surveillance by sentinel GPs
[3,22,23,29-33]. Although there is an approximately parallel
rise, peak and decline of ILI activity between the Influenzanet
and EISN epidemic curves, the incidence values obtained by
Influenzanet are quantitatively higher than those collated by
ECDC. For instance, Influenzanet ILI incidence rates in the
Netherlands were found to be 5 to 10 times higher during the
winters of 2010-11 to 2015-16 (when restricted to the period of
virological influenza confirmation by the Dutch Sentinel Practice
Network). Specifically, the percentage of ILI cases in the Dutch
influenzanet volunteers ranged from 6% (616/10,803) to 14%
(1532/11,034) during an observation period of 22 weeks,
whereas the Dutch Sentinel Practice Network rates for the same
period ranged from 0.8% to 2% (840 to 2220 per 100,000
patients) (unpublished data). Higher incidence rates in
Influenzanet versus sentinel surveillance also occur in other
participating countries, although the magnitude of the difference
varies by country [22,30,32,33].
The greater magnitude of the incidence rates estimated by
Influenzanet versus sentinel surveillance networks might
possibly be partially explained by health care-seeking behavior,
as this differs across countries. People may not seek medical
care for a variety of reasons such as disease severity or
sociodemographic differences and thus not be accounted as ILI
cases by the traditional sentinel surveillance system [22].
Influenzanet allows estimating the fraction of the population
with symptoms that seeks health care services, as this is a
follow-up question asked to participants in the symptoms
questionnaire. The data have shown that this fraction varies
greatly by country [22], being also dependent on the severity
of symptoms (and therefore, on the ILI case definition used
[33,34]) and the season [22,34].
Textbox 1. Influenza-like illness case definitions.
The following case definition for influenza-like illness (ILI) is recommended by the European Centre for Disease Control and Prevention (ILIecdc).
From season 2011-12 onwards, all countries participating in Influenzanet use the same questionnaires and apply this case definition when reporting
feedback to participants on whether their reported symptoms might be due to ILI:
• Sudden onset of symptoms;
• AND at least 1 of the following systemic symptoms: Fever or feverishness (chills), Malaise, Headache, Muscle pain;
• AND at least 1 of these respiratory symptoms: Cough, Sore throat, Shortness of breath.
During the first seasons of Influenzanet, the questionnaire did not include some of the symptoms above; additionally, participants could only report
fever if they measured their temperature. Therefore, the ILIecdc definition could not be applied. To overcome this and to allow comparing data across
seasons, the following case definition was developed (ILIhist, for historic reasons):
• Sudden onset of symptoms;
• AND Fever (≥38°C temperature);
• AND at least 1 of these systemic symptoms: Headache, Muscle pain;
• AND at least 1 of these respiratory symptoms: Cough, Sore throat
ILIecdc has a higher sensitivity, because more participants with influenza will fit the definition. Conversely, ILIhist has a higher specificity, since fewer
participants who do not have influenza will fit the definition.
The ILIhist case definition was first used in the Netherlands and Belgium in 2003 to closely match the Dutch general practitioners’ ILI case definition
(sudden onset of symptoms with a prodromal phase of an already existing nonsickening respiratory infection of at the most 3 to 4 days; and fever
(≥38°C temperature); and at least one of the following symptoms: cough, runny nose, sore throat, frontal headache, retrosternal pain, or muscle pain).
In addition to these, multiple case definitions can be used within the Influenzanet system to analyze the symptoms data provided by the participants.
The percentage of participants with ILI who sought medical
care was shown to be lower in northern Europe (except Belgium)
than in southern Europe [22]. For instance, in the 2013-14
season, Danish Influenzanet data have demonstrated that the
fraction of Danish participants with ILI who visited a GP ranged
between 16% (31/192), 22% (92/413), and 34% (33/97), when
considering the ILI case definition used by Danish GPs, ECDC,
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or the alternative ILIhist definition, respectively ([33],
complemented by Influenzanet unpublished data). In Belgium,
a higher fraction of volunteers with ILI reported visiting a health
care professional (71%, 112/158 ILIhist), possibly because
according to the Belgian law, an employer can require from its
employee a medicaI statement within 24 hours to justify work
absenteeism ([22], complemented by Influenzanet unpublished
data).
Among the Influenzanet volunteers who did seek medical care,
in southern Europe (France, Italy, Portugal, and Spain) and
Belgium, the participants reported to generally visit a GP within
1 to 2 days after the onset of ILI symptoms, whereas in northern
Europe (Sweden, the United Kingdom, the Netherlands,
Denmark) with the exception of Belgium, participants generally
sought medical care only 5 to 7 days after the onset of symptoms
[22]. In countries where participants wait longer before seeking
medical care, many ILI cases may no longer feel sufficiently ill
to warrant a visit to a health care professional and therefore are
not accounted as ILI cases by the traditional sentinel surveillance
system [22,30].
This variation across countries in the rates of seeking medical
care is one of the reasons why ILI incidence reported by ECDC
cannot be compared directly between countries. Another reason
is the disparities in ILI case definitions used by GPs in different
countries. For example, many national surveillance systems do
not apply the ILI definition recommended by ECDC, where
fever is not mandatory but instead apply an ILI case definition
that does require fever, especially to distinguish between an
influenza infection and a common cold [22].
Estimates of disease burden can be informative for public health
policy decisions regarding the prioritization of interventions
and preventive measures. As the traditional health care-based
surveillance tends to underestimate the true burden of disease
in the population, Influenzanet can be used as a supplemental
data source to obtain a more comprehensive estimate of the true
disease burden [35]. It could also target the economic burden,
including direct costs through health care as well as the indirect
socioeconomic costs (school and work absenteeism); it could
additionally contribute to estimate the cost-effectiveness of
vaccination.
Identification of Risk Factors
The primary risk factor for acquiring an ILI infection is having
direct or indirect contact with an infectious person. Analyses
of individual-level data provided by the Influenzanet volunteers
in the Netherlands, Belgium, Portugal, and Italy allowed
identifying the following factors as additional independent
predictors of increased risk of having at least one ILI episode
during an influenza season [22]: having a chronic disease
(asthma, diabetes, heart disease, and/or an
immunocompromising condition), living with at least 1 child,
belonging to a younger age group (<18 years of age), having
one or more allergies (hay fever, dust mite allergy and allergy
to cats and/or dogs), and being a smoker.
Seniors are generally considered a risk group for influenza, not
because of a higher probability of infection but because of their
greater risk for complications and increase in expected mortality
[36,37]. In the Influenzanet study [22], the risk of ILI among
participants over the age of 65 years was smaller than in the
other age groups. This was not because of the higher uptake of
influenza vaccine in seniors, as the risk factor analysis accounted
for that factor by including vaccination status as a separate
covariate in the multivariate model. The reduced risk among
seniors may possibly be attributed to immunity from past
exposures (ie, either from prior influenza infections and/or
vaccinations). Immune responses of older adults are often
markedly stronger than those of younger individuals for some
influenza strains (eg, for A/H1N1 that circulated between 1918
and 1957 and that was reintroduced in 1976 and with a pandemic
subtype in 2009) but are more similar for others (eg, A/H3N2
that has circulated since 1968; [38]). Alternatively, or
additionally, the reduced risk among seniors may possibly also
be because of a smaller contact rate with infectious individuals.
A small risk reduction was also observed in Influenzanet
participants who practiced more than 1 hour of sports per week.
Finally, public transportation did not appear to increase the risk
of developing ILI relative to driving a car, riding a bicycle, or
walking as a primary mode of transportation [22]. The results
of these risk factor analyses have been shown to be consistent
across all Influenzanet countries [39].
The identification of ILI risk factors is one of two main ways
that ILI surveillance data have been used to gain a better
understanding of ILI control and prevention; the evaluation of
intervention effectiveness is another, as discussed in the next
section.
Influenza Vaccine Effectiveness
Vaccination to prevent influenza is particularly important for
people who are at a higher risk of developing serious
complications if they get sick with influenza. According to
WHO, the recommended risk groups for vaccination are as
follows: all people ≥6 months of age with a chronic disease,
children aged 6 to 59 months, pregnant women, residents of
long-term care facilities, health care workers, and elderly (often
defined as aged ≥65 years, but defined as aged ≥60 years in the
Netherlands; [37]). The ability of an influenza vaccine to protect
someone depends not only on the age and health status of the
person getting the vaccine but also on the similarity or “match”
between the virus strains in the vaccine and those in circulation.
Effectiveness against ILI is therefore expected to be lower for
influenza, as the influenza vaccine targets specifically the
influenza virus and not other ILI. According to a large
meta-analysis of 90 reports containing 116 datasets of
randomized or quasi-randomized studies of VE in healthy adults,
the overall effectiveness of inactivated parenteral influenza
vaccines was estimated to be 16% (95% CI 5-25) against ILI
and 60% (95% CI 53-66) against confirmed influenza [40].
Ideally, large-scale randomized controlled trials should be
undertaken to assess vaccine efficiency, but it is impractical to
conduct them every year. Also, because of global
recommendations for influenza vaccination, placebo-controlled
trials that could clarify the effects of influenza vaccines in
individuals are no longer considered possible on ethical grounds
[41]. For these reasons, most data on influenza VE come from
observational studies.
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The I-MOVE (Influenza-Monitoring Vaccine Effectiveness)
network [42] aims at measuring influenza VE in Europe and
has been operating since 2007, coordinated by ECDC. Eight
study sites (Germany, Hungary, Ireland, Italy, Poland, Portugal,
Romania, and Spain) participated in the test-negative 2014-15
multicenter case–control study [43]. The methods are based on
the ECDC generic case–control study protocol [44]. Participating
GPs interviewed (collecting clinical and epidemiological
information) and collected nasopharyngeal specimens from
patients consulting for ILI aged ≥60 years (Germany, Poland,
and 3 regions in Spain), or ≥65 years (Hungary, Ireland, Italy,
Portugal, Romania, and 3 regions in Spain), and from a
systematic sample of ILI patients in the other age groups. Only
patients who presented to the GPs more than 14 days after the
start of the national vaccination campaigns and who met the
ECDC ILI case definition, and who had not received antivirals
before swabbing, were swabbed within 7 days of symptom
onset. For the 2014-15 season, the overall VE against influenza
A(H3N2) was 14.4% (95% CI −6.3 to 31.0), against
A(H1N1)pdm09 was 54.2% (95% CI 31.2-69.6), and against
B was 48.0% (95% CI 28.9-61.9).
Because Influenzanet also collects data on whether participants
have been vaccinated for influenza, it allows measurement of
ILI incidence in the self-reporting cohorts of vaccinated and
unvaccinated participants, and therefore, the system could
potentially be used as a complementary tool to measure the
effectiveness of the influenza vaccine against ILI close to real
time [45].
Several of the Influenzanet national project teams have carried
out studies to assess VE among participants during specific
years. For example, UK Influenzanet data were used to estimate
the effectiveness of the influenza vaccine in the postpandemic
influenza season of 2010-11 [46]. In that study, vaccination for
seasonal influenza in combination with the vaccination against
the pandemic influenza the previous year was associated with
reduced ILI incidence, with an estimated VE of 52% (95% CI
27-68). It was also associated with reduced absenteeism,
especially for those between 25 and 64 years of age, with 4.1%
of the vaccinated participants reporting taking time off work
because of symptoms, compared with 11.6% of the unvaccinated
persons (P<.001). Furthermore, vaccinated absentees were away
from work for a significantly shorter period of time compared
with the unvaccinated persons.
In France, the effectiveness of the 2012-13 influenza vaccine
against ILI (defined by cough and fever ≥38oC in that study)
was estimated as 49% (95% CI 20-67; P<.001) for the overall
population and 32% (95% CI 0-58; P=.10) for the population
at risk of developing influenza-related complications, based on
data from Influenzanet participants in that season [47].
In the Netherlands, between 2003-04 and 2012-13, a reduction
in ILI among vaccinated Influenzanet participants was estimated
in 4 seasons (2007-08, 2008-09, 2010-11, and 2012-13), whereas
in the other 6 seasons no statistically significant effect was
observed [22]. The VE for all participants varied between 33%
(95% CI 22-42) in 2010-11 and −10% (95% CI −28 to 6) in
2004-05. In addition to 2004-05, a negative although likewise
nonstatistically significant VE was also estimated for 2003-04,
both being seasons with a poor vaccine match with the
circulating influenza virus strains [48].
Additional VE Analyses
There are a few important considerations when using
Influenzanet data as a complementary tool to estimate the
effectiveness of the influenza vaccine. The influenza vaccine
only protects against the influenza virus, but ILI may be caused
by other infections. Additionally, vaccinated and unvaccinated
participants cannot be compared directly, as participants who
decide to take the vaccination may do so because they belong
to a risk group, for instance, those with a chronic disease or
those of older age; thus, differences in ILI rate between
vaccinated and unvaccinated participants can be because of
either the vaccine or an a priori difference between both groups
[32]. Finally, influenza infections may develop
asymptomatically.
At the request of the National Institute for Health and the
Environment in the Netherlands, we estimated VE in the Dutch
Influenzanet participants for the 2014-15 [49] and 2015-16 [50]
seasons, stratified by age and underlying chronic disease, as the
number of samples collected by the GPs sentinel networks was
too low to allow for these stratified analyses. With 14,000
participants overall yearly, the Dutch Influenzanet database
covers 0.08% of the 17 million population in the Netherlands.
This large size warrants estimates of VE stratified for particular
risk groups, namely, the presence of chronic conditions and
older age. Here, we present these estimates, addressing the top
two abovementioned considerations. Notably, we considered
only the ILI cases in the weeks when there was virological
confirmation of influenza by the Dutch Sentinel Practice
Network, and of these cases, we used only the number of ILI
cases above a seasonal baseline incidence for nonepidemic ILI.
By excluding the weeks when there was no virological
confirmation of influenza, we excluded the period when most
ILI cases were likely because of noninfluenza infections; and
by considering only the number of ILI cases above the typical
number of ILI cases measured in the absence of circulating
viruses, one can therefore obtain a more accurate proxy of VE
against influenza. The VE calculated in this way is here
designated as VE(influenza), also shown in Figure 3 (see
Multimedia Appendix 2 for further details).
If considering the full period of 25 weeks during which
Influenzanet collected data (mid-November to the end of April),
then the estimated VE against ILI (ie, VE(ILI) in Multimedia
Appendix 2) is considerably low. However, VE increases
substantially when considering only ILI onsets during the weeks
of virological confirmed influenza (17 weeks in 2014-15, 11
weeks in 2015-16) and subtracting the seasonal baseline (ie,
VE(influenza) in Table A1 and Figure 3). Namely, the estimated
VE in chronic patients almost doubled when considering only
the influenza epidemic period with the baseline subtracted, that
is, VE(Influenza)~41% in both seasons, compared with when
considering the whole data collection period, that is,
VE(ILI)~25% in both seasons; even greater VE increases were
found for the participants with a chronic condition over 60 years
of age (VE=62% [95% CI 40-76] in 2014-15 and 53% [95%
CI 6-77] in 2015-16).
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Figure 3. Influenza vaccine effectiveness (VE) in the Netherlands estimated with Influenzanet data during the period of virological confirmed influenza
in the 2014-2015 and 2015-2016 seasons. VE(influenza) for all participants and stratified for age and chronic illness, based on self-reported influenza-like
illness. The error bars denote the VE 95% CI. (In the "60+ and no chronic illness” stratification it was not possible to calculate the CI in 2014-2015 due
to zero ILI cases in the vaccinated group).
The 2014-15 season had a circulating influenza A(H3N2) virus
that mismatched with the strain in the vaccine [49]. The 2015-16
season had 2 circulating strains, A(H1N1) and A(H3N2), which
appeared to be covered by the vaccine, although there was some
mismatch between cocirculating influenza B Victoria compared
with B Yamagata in the vaccine [50]. Hence, one would expect
not very high VE against influenza in both seasons but higher
in 2015-16, given that this season had a better match between
the circulating and the vaccine strains. Our results do indeed
reflect this pattern, with the estimated VE(influenza) for all
participants being greater in 2015-16 (34%; 95% CI 18-46) than
in 2014-15 (2%; 95% CI −17 to 18). Interestingly, however, the
VE(influenza) in chronic patients was the same in both seasons
(41% [95% CI 16-59] in 2015-16 and 41% [95% CI 24-65] in
2014-15). Although in both seasons among chronic patients,
the VE(influenza) in participants ≥60 years seemed to be higher
than in younger ones (which would seem to go against the
current hypothesis that immunosenescense in the elderly results
in lower VE [51]), we cannot make direct comparisons with
participants aged under 60 years because of the nonstatistically
significant estimated VE P values. A larger number of
participants would be required to make stronger conclusions.
Care should be taken that results of this and the other
abovementioned VE studies [22,40,45-47] should not be
compared directly, as ILI definitions varied and different
methods were used in computing VE.
Discussion
Further Studies
The Influenzanet system gathers a variety of valuable data on
ILI activity. The analyses of Influenzanet data summarized in
this paper reflect only a portion of what is possible. Influenzanet
has the potential to monitor the geographical spread of ILI using
the postal codes of the participants. Additionally, demographic
data could be used to monitor ILI activity in different more or
less vulnerable subgroups of the population. Moreover, extra
questions can be included in the Web-based intake questionnaire
at any time and entire new questionnaires added in any particular
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season. For instance, a stress-related questionnaire was added
in the Netherlands in the 2004-05 season, revealing significant
trends between stress/personality and self-reported ILI [52].
Multivariable logistic regression analysis on ILI was performed
to test the predictive power of stress and personality. Negative
affectivity (Odds ratio [OR] 1.05, P=.009), social inhibition
(OR 0.97, P=.01), and perceived stress (OR 1.03, P=.048)
predicted ILI reporting. Older age was associated with less ILI
reporting (OR 0.98, P=.01).
Also in the Netherlands, additional information was collected
during the 2009-10 season, on the occurrence of adverse events
after administration of the seasonal and pandemic influenza
vaccines using either a traditional paper-based survey (for which
participants were recruited via GPs) or a Web-based survey (for
which participants were recruited via the Dutch Influenzanet;
[53]). No significant differences were found in reporting local
reactions (OR 0.98, 95% CI 0.88-1.10) or systemic adverse
events (OR 1.12, 95% CI 0.99-1.27). There were, however,
important differences in the age groups that responded. Namely,
the elderly were more represented in the paper-based than in
the Web-based survey. Additionally, in both surveys, females
reported more local reactions and systemic adverse events than
males, the risk of side effects decreased with age, and the
presence of a comorbidity increased the risk of local reactions
and systemic adverse events.
In other studies of the Influenzanet data in the United Kingdom
[54] and the Netherlands [55,56], the analyses of questionnaires
related to contact behavior have shown that the changes in
contact patterns can explain alterations in disease incidence [54]
and that Web-based respondent-driven detection could enhance
identification of symptomatic patients by making use of
individuals’ local social networks [55,56]. Respondent-driven
detection could enable a greater diversity in the age and social
status of the participatory surveillance participants, thereby
improving the representativeness of the study population and
possibly also allow more accurate estimates of the effect of
influenza vaccination. One would, however, also need to take
into consideration that the proportion of ILI in the study sample
could increase because of the participation of a select group of
participatory surveillance volunteers with ILI symptoms, as has
been observed in the study that tested this approach [56].
Finally, data validation is key to greater acceptance and
credibility in the field of public health. In winter, the sentinel
GPs that integrate the EISN are asked to take nose and/or throat
swabs from a subset of patients with ILI for virological
determination. These data inform the national and international
decisions by health policy makers. The GP samples, however,
do not cover the large part of the population that does not seek
medical health care for ILI. A system of self-sampling (ie,
swabbing nostrils and/or throat and then sending the swabs for
virological testing) among Influenzanet participants could help
to overcome this limitation.
This approach has been piloted outside the Influenzanet context
by the national public health agencies in both the United
Kingdom [57] and Sweden [58]. In the United Kingdom study,
a group of 294 callers to the national telephone health helpline
(National Health Service Direct) who mentioned colds or
influenza were sent a self-sampling kit. They were asked to
swab both nostrils and then send the swabs for influenza virus
testing. About half the callers sent back the samples, and most
did not experience problems in taking the test. The average time
between the call and the results of the laboratory was 7 days.
The overall influenza-positive rate (16%, 23/142) was lower
than in the national virological surveillance system of the United
Kingdom (26%), but peak positivity for both the schemes
occurred during the same week. This study showed that people
can self-sample in a reasonable time frame and that these
samples were viable for antigenic characterization and molecular
detection, which decreases the need for medical personnel to
obtain samples. Self-sampling by the callers provided among
the earliest reports of influenza circulating in the community
and led to the detection of several strains of the virus [57]. These
encouraging results have led to a self-sampling study with
Influenzanet participants being planned in the United Kingdom
to strengthen the validation of the participatory surveillance
data.
We also plan to integrate the Influenzanet data with social
networks, news streams, health forums, clinical records, and
routine data to have a better understanding of the socioeconomic
aspects of ILI epidemics in Europe and some behavioral insights
on, for example, attitude toward influenza vaccination.
Early Warning
Detecting an earlier rise of ILI activity in certain subgroups
could make Influenzanet a fast early-warning system. Indeed,
it is often suggested that self-reporting surveillance systems
might be able to detect changes in disease activity earlier than
the traditional surveillance systems [32,33,59,60]. This is
because of the self-reported data becoming instantaneously
available for automated analyses, whereas in the traditional
systems there is a delay from when data are collected in the
medical facilities until they are available for centralized analyses.
However, run-time detection of disease activity above baseline
should not be confused with detection of a newly emerging
disease. For a participatory surveillance system such as
Influenzanet to become a viable system for early warning of
the first cases of a new disease, a greater proportion of the
population needs to be engaged [32]; so far the platform has
been able to recruit at the most 0.08% of a country's population.
For Influenzanet to become a European-level early warning
system for serious cross-border health threats, all European
countries would need to participate. Additional research is also
needed to identify the best way to differentiate a signal caused
by an influenza epidemic with one caused by a “new disease”
of a respiratory nature, or producing respiratory symptoms, and
how to set that threshold.
Continuity and Sustainability
Recruitment and Participation
The added value that the Influenzanet system brings to ILI
surveillance depends on recruiting and retaining as many active
participants as possible, covering a wide geographical area and
from diverse age and risk groups.
Although specific Influenzanet recruitment strategies vary
between countries, they tend to be based on mass communication
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[61,62]. Participants are recruited through press releases, direct
mailings to schools, and interviews on national and local
television and radio, in national and regional newspapers, and
on social media. Schools are also provided with educational
material on influenza to promote incorporation of disease
surveillance concepts in science classes. At the beginning of
each season, all participants from previous seasons are sent an
email, inviting them to participate again by completing an intake
questionnaire for the new season.
An important cornerstone for enhancing active participation is
the information feedback offered to participants. The participants
receive weekly emails containing a newsletter with
country-specific data and influenza-related news articles written
by professional science journalists, which helps keeping them
involved and motivated.
From a science communication point of view, an interesting
finding from the Dutch project is that Influenzanet has been
able to attract and keep engaged many people without previous
experience in scientific research, citizen science projects, or
science activities in their daily lives. This contradicts previous
findings that participants may be restricted to a self-selected
group with previous experience and interest in science [63].
One way the Dutch Influenzanet reaches out to both current and
potential participants is by having a well-known science
communicator serve as the ambassador of the project. Other
Influenzanet countries have also experienced the importance of
having science communication experts working alongside
scientists in the project to reach the general public. It is
important to emphasize how participants have contributed to
the findings and the success of the project and that their
continued contributions are valued [4].
Sustainability
Influenzanet is low-cost to run in comparison with traditional
systems. However, it is not free of costs and needs active support
to continue, especially where self-swabbing, in addition to
self-reporting, is concerned. Funding for Influenzanet is also
vital for the project's maintenance, in particular to keep
participants actively engaged via the weekly newsletter and
social media interaction, to further improve the national
platforms and to keep recruiting new participants by providing
the media with the latest news and results. Also, acceptance
must be sought among influenza health care professionals so
that the results can be displayed and used along with other
surveillance and response systems.
From 2009 to 2013, the European Union’s FP7 project,
EPIWORK, made it possible to extend the Influenzanet system,
which at the time included only the Netherlands, Belgium,
Portugal, and Italy, into 6 additional European countries.
Influenza monitoring with self-reporting volunteers is now
active in 10 European countries [39]. With the exception of the
Netherlands and Belgium, where Influenzanet is run by a small
private company, in all other countries it is coordinated by teams
in national research and/or public health institutions.
Conclusions
Influenzanet can complement traditional health care–based
systems by providing data that are not otherwise available.
Influezanet is able to achieve this because it allows collecting
data also from people who do not seek health care (and are
therefore not accounted in traditional ILI surveillance), and it
additionally gathers detailed information about the participants
that is not routinely collected elsewhere. Due to its uniform
nature across countries, it both allows for direct comparisons
of ILI activity between countries and provides a platform to
monitor the geographical spread of ILI throughout Europe.
Moreover, Influenzanet provides an important channel for
influenza awareness and health literacy in Europe. With its
speed and flexibility, the system could be extended to detect
diseases other than influenza, including those that emerge in
low-income settings such as dengue, leptospirosis, severe acute
respiratory syndrome, Ebola, Middle East respiratory syndrome,
and Zika virus, and where community engagement is vital
[35,64-66]. If so, this novel Internet monitoring system based
on voluntary participants could develop into an important
weapon to fight influenza as well as other contagious diseases
globally. Influenzanet in Europe is an example of best practice
here, not only by engaging citizens to report information that
enables to complement the data obtained by traditional disease
surveillance systems but also by providing a flexible and wide
reach health literacy channel, delivering back reliable and
updated information to the population about disease activity,
transmission, and prevention strategies. During the second
International Workshop on Participatory Surveillance
(Amsterdam, the Netherlands, April 15-17, 2013) a letter of
intent on cooperation and data exchange has been agreed
between Influenzanet, Flu Tracking, and Flu Near You. The
aim is to achieve a worldwide “disease radar,” whereby everyone
is invited to fill in their own health status.
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